No Data
Lyell Immunopharma Is Maintained at Buy by B of A Securities
Lyell Immunopharma Is Maintained at Buy by B of A Securities
B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6
B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $9 to $6.
Lyell Immunopharmashares Are Trading Lower After the Company Released Initial Clinical Data From Its Phase 1 Trial of LYL797.
Lyell Immunopharmashares Are Trading Lower After the Company Released Initial Clinical Data From Its Phase 1 Trial of LYL797.
Lyell Immunopharma Price Target Cut to $1.00/Share From $6.00 by HC Wainwright & Co.
Lyell Immunopharma Price Target Cut to $1.00/Share From $6.00 by HC Wainwright & Co.
Express News | HC Wainwright & Co. Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $1
Express News | Lyell Immunopharma, Inc. : H.c. Wainwright Cuts to Neutral From Buy